 SOUTH SAN FRANCISCO, Calif., June 04, 2021 GLOBE NEWSWIRE -- Harpoon Therapeutics, Inc. NASDAQ: HARP, a clinical-stage immunotherapy company developing a novel class of T cell engagers, today provided a pipeline update on its four clinical stage programs, including updating the interim data presented earlier today at ASCO from the ongoing dose escalation portion of the Phase 12a trial for HPN424 in patients with metastatic castration resistant prostate cancer mCRPC. Harpoon has four product candidates in clinical trials that are based on its proprietary Tri-specific T cell Activating Construct TriTAC platform designed to recruit a patients own immune cells to kill tumor cells. 